#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Debilitating , unexplained provoked localized vulvar pain or vulvodynia affects a significant proportion ( ~8 % ) of women and is epidemiologically linked to a history of both seasonal and contact allergies .
3-1	17-29	Debilitating	_	_	_	_
3-2	30-31	,	_	_	_	_
3-3	32-43	unexplained	abstract[3]|abstract[4]	new[3]|new[4]	coref|coref|coref|coref	5-22[24_3]|6-34[39_4]|5-22[24_3]|6-34[39_4]
3-4	44-52	provoked	abstract[3]|abstract[4]	new[3]|new[4]	_	_
3-5	53-62	localized	abstract[3]|abstract[4]	new[3]|new[4]	_	_
3-6	63-69	vulvar	abstract[3]|abstract[4]	new[3]|new[4]	_	_
3-7	70-74	pain	abstract[3]|abstract[4]	new[3]|new[4]	_	_
3-8	75-77	or	abstract[4]	new[4]	_	_
3-9	78-88	vulvodynia	abstract[4]|substance	new[4]|new	coref	12-22
3-10	89-96	affects	_	_	_	_
3-11	97-98	a	quantity[6]	new[6]	appos	3-15[7_6]
3-12	99-110	significant	quantity[6]	new[6]	_	_
3-13	111-121	proportion	quantity[6]	new[6]	_	_
3-14	122-123	(	_	_	_	_
3-15	124-126	~8	quantity[7]	giv[7]	_	_
3-16	127-128	%	quantity[7]	giv[7]	_	_
3-17	129-130	)	_	_	_	_
3-18	131-133	of	_	_	_	_
3-19	134-139	women	person	new	_	_
3-20	140-143	and	_	_	_	_
3-21	144-146	is	_	_	_	_
3-22	147-164	epidemiologically	_	_	_	_
3-23	165-171	linked	_	_	_	_
3-24	172-174	to	_	_	_	_
3-25	175-176	a	abstract[9]	new[9]	_	_
3-26	177-184	history	abstract[9]	new[9]	_	_
3-27	185-187	of	abstract[9]	new[9]	_	_
3-28	188-192	both	abstract[9]|abstract[10]	new[9]|new[10]	_	_
3-29	193-201	seasonal	abstract[9]|abstract[10]	new[9]|new[10]	_	_
3-30	202-205	and	abstract[9]|abstract[10]	new[9]|new[10]	_	_
3-31	206-213	contact	abstract[9]|abstract[10]	new[9]|new[10]	_	_
3-32	214-223	allergies	abstract[9]|abstract[10]	new[9]|new[10]	_	_
3-33	224-225	.	_	_	_	_

#Text=Vulvar biopsies from diagnosed patients show increases in mast cells and nerves .
4-1	226-232	Vulvar	person|abstract[12]	new|new[12]	coref|coref	11-24|11-24
4-2	233-241	biopsies	abstract[12]	new[12]	_	_
4-3	242-246	from	abstract[12]	new[12]	_	_
4-4	247-256	diagnosed	abstract[12]|person[13]	new[12]|new[13]	_	_
4-5	257-265	patients	abstract[12]|person[13]	new[12]|new[13]	_	_
4-6	266-270	show	_	_	_	_
4-7	271-280	increases	event[14]	new[14]	_	_
4-8	281-283	in	event[14]	new[14]	_	_
4-9	284-288	mast	event[14]|object|object[16]	new[14]|new|new[16]	coref|coref|coref|coref	6-42[41_16]|7-5|6-42[41_16]|7-5
4-10	289-294	cells	event[14]|object[16]	new[14]|new[16]	_	_
4-11	295-298	and	event[14]	new[14]	_	_
4-12	299-305	nerves	event[14]|abstract	new[14]|new	_	_
4-13	306-307	.	_	_	_	_

#Text=To recapitulate and dissect the pathobiology of allergy-driven tactile sensitivity and to inform novel therapies , we established mouse models of allergy-driven genital pain .
5-1	308-310	To	_	_	_	_
5-2	311-323	recapitulate	_	_	_	_
5-3	324-327	and	_	_	_	_
5-4	328-335	dissect	_	_	_	_
5-5	336-339	the	abstract[18]	new[18]	_	_
5-6	340-352	pathobiology	abstract[18]	new[18]	_	_
5-7	353-355	of	abstract[18]	new[18]	_	_
5-8	356-370	allergy-driven	abstract[18]|abstract[19]	new[18]|new[19]	coref	16-43[138_19]
5-9	371-378	tactile	abstract[18]|abstract[19]	new[18]|new[19]	_	_
5-10	379-390	sensitivity	abstract[18]|abstract[19]	new[18]|new[19]	_	_
5-11	391-394	and	_	_	_	_
5-12	395-397	to	_	_	_	_
5-13	398-404	inform	_	_	_	_
5-14	405-410	novel	abstract[20]	new[20]	_	_
5-15	411-420	therapies	abstract[20]	new[20]	_	_
5-16	421-422	,	_	_	_	_
5-17	423-425	we	person	acc	ana	6-1
5-18	426-437	established	_	_	_	_
5-19	438-443	mouse	animal|abstract[23]	new|new[23]	coref|coref|coref|coref	13-4|13-1[111_23]|13-4|13-1[111_23]
5-20	444-450	models	abstract[23]	new[23]	_	_
5-21	451-453	of	abstract[23]	new[23]	_	_
5-22	454-468	allergy-driven	abstract[23]|abstract[24]	new[23]|giv[24]	coref	6-34[38_24]
5-23	469-476	genital	abstract[23]|abstract[24]	new[23]|giv[24]	_	_
5-24	477-481	pain	abstract[23]|abstract[24]	new[23]|giv[24]	_	_
5-25	482-483	.	_	_	_	_

#Text=We have shown that contact hypersensitivity to the commonly used laboratory haptens oxazolone ( Ox ) on the labiar skin or dinitrofluorobenzene ( DNFB ) on the labiar skin or vaginal canal induces persistent tactile genital pain and increased accumulation of mast cells in the labiar tissues of outbred , female ND4 mice well beyond the resolution of visible inflammation .
6-1	484-486	We	person	giv	ana	8-3
6-2	487-491	have	_	_	_	_
6-3	492-497	shown	_	_	_	_
6-4	498-502	that	_	_	_	_
6-5	503-510	contact	_	_	_	_
6-6	511-527	hypersensitivity	abstract[26]	new[26]	coref	8-21[0_26]
6-7	528-530	to	abstract[26]	new[26]	_	_
6-8	531-534	the	abstract[26]|substance[29]	new[26]|new[29]	_	_
6-9	535-543	commonly	abstract[26]|substance[29]	new[26]|new[29]	_	_
6-10	544-548	used	abstract[26]|substance[29]	new[26]|new[29]	_	_
6-11	549-559	laboratory	abstract[26]|place|substance[29]	new[26]|new|new[29]	_	_
6-12	560-567	haptens	abstract[26]|animal|substance[29]	new[26]|new|new[29]	_	_
6-13	568-577	oxazolone	abstract[26]|substance[29]	new[26]|new[29]	_	_
6-14	578-579	(	_	_	_	_
6-15	580-582	Ox	person	new	_	_
6-16	583-584	)	_	_	_	_
6-17	585-587	on	_	_	_	_
6-18	588-591	the	object[31]|abstract[32]	new[31]|new[32]	coref|coref|coref|coref	6-27[35_31]|6-27[36_32]|6-27[35_31]|6-27[36_32]
6-19	592-598	labiar	object[31]|abstract[32]	new[31]|new[32]	_	_
6-20	599-603	skin	object[31]|abstract[32]	new[31]|new[32]	_	_
6-21	604-606	or	abstract[32]	new[32]	_	_
6-22	607-627	dinitrofluorobenzene	abstract[32]|substance	new[32]|new	_	_
6-23	628-629	(	_	_	_	_
6-24	630-634	DNFB	object	new	_	_
6-25	635-636	)	_	_	_	_
6-26	637-639	on	_	_	_	_
6-27	640-643	the	object[35]|abstract[36]	giv[35]|giv[36]	coref|coref|coref|coref	10-31[87_35]|10-31[88_36]|10-31[87_35]|10-31[88_36]
6-28	644-650	labiar	object[35]|abstract[36]	giv[35]|giv[36]	_	_
6-29	651-655	skin	object[35]|abstract[36]	giv[35]|giv[36]	_	_
6-30	656-658	or	abstract[36]	giv[36]	_	_
6-31	659-666	vaginal	abstract[36]|place[37]	giv[36]|new[37]	coref	7-21[53_37]
6-32	667-672	canal	abstract[36]|place[37]	giv[36]|new[37]	_	_
6-33	673-680	induces	_	_	_	_
6-34	681-691	persistent	abstract[38]|abstract[39]	giv[38]|giv[39]	coref|coref	7-25[54_38]|7-25[54_38]
6-35	692-699	tactile	abstract[38]|abstract[39]	giv[38]|giv[39]	_	_
6-36	700-707	genital	abstract[38]|abstract[39]	giv[38]|giv[39]	_	_
6-37	708-712	pain	abstract[38]|abstract[39]	giv[38]|giv[39]	_	_
6-38	713-716	and	abstract[39]	giv[39]	_	_
6-39	717-726	increased	abstract[39]|abstract[40]	giv[39]|new[40]	_	_
6-40	727-739	accumulation	abstract[39]|abstract[40]	giv[39]|new[40]	_	_
6-41	740-742	of	abstract[39]|abstract[40]	giv[39]|new[40]	_	_
6-42	743-747	mast	abstract[39]|abstract[40]|object[41]	giv[39]|new[40]|giv[41]	coref	7-4[48_41]
6-43	748-753	cells	abstract[39]|abstract[40]|object[41]	giv[39]|new[40]|giv[41]	_	_
6-44	754-756	in	abstract[39]|abstract[40]|object[41]	giv[39]|new[40]|giv[41]	_	_
6-45	757-760	the	abstract[39]|abstract[40]|object[41]|place[42]	giv[39]|new[40]|giv[41]|new[42]	_	_
6-46	761-767	labiar	abstract[39]|abstract[40]|object[41]|place[42]	giv[39]|new[40]|giv[41]|new[42]	_	_
6-47	768-775	tissues	abstract[39]|abstract[40]|object[41]|place[42]	giv[39]|new[40]|giv[41]|new[42]	_	_
6-48	776-778	of	abstract[39]|abstract[40]|object[41]|place[42]	giv[39]|new[40]|giv[41]|new[42]	_	_
6-49	779-786	outbred	abstract[39]|abstract[40]|object[41]|place[42]	giv[39]|new[40]|giv[41]|new[42]	_	_
6-50	787-788	,	abstract[39]|abstract[40]|object[41]|place[42]	giv[39]|new[40]|giv[41]|new[42]	_	_
6-51	789-795	female	abstract[39]|abstract[40]|object[41]|place[42]|animal[43]	giv[39]|new[40]|giv[41]|new[42]|new[43]	coref	8-29[68_43]
6-52	796-799	ND4	abstract[39]|abstract[40]|object[41]|place[42]|animal[43]	giv[39]|new[40]|giv[41]|new[42]|new[43]	_	_
6-53	800-804	mice	abstract[39]|abstract[40]|object[41]|place[42]|animal[43]	giv[39]|new[40]|giv[41]|new[42]|new[43]	_	_
6-54	805-809	well	abstract[39]|abstract[40]|object[41]|place[42]|animal[43]	giv[39]|new[40]|giv[41]|new[42]|new[43]	_	_
6-55	810-816	beyond	abstract[39]|abstract[40]|object[41]|place[42]|animal[43]	giv[39]|new[40]|giv[41]|new[42]|new[43]	_	_
6-56	817-820	the	abstract[39]|abstract[40]|object[41]|place[42]|animal[43]|abstract[44]	giv[39]|new[40]|giv[41]|new[42]|new[43]|new[44]	_	_
6-57	821-831	resolution	abstract[39]|abstract[40]|object[41]|place[42]|animal[43]|abstract[44]	giv[39]|new[40]|giv[41]|new[42]|new[43]|new[44]	_	_
6-58	832-834	of	abstract[39]|abstract[40]|object[41]|place[42]|animal[43]|abstract[44]	giv[39]|new[40]|giv[41]|new[42]|new[43]|new[44]	_	_
6-59	835-842	visible	abstract[39]|abstract[40]|object[41]|place[42]|animal[43]|abstract[44]|abstract[45]	giv[39]|new[40]|giv[41]|new[42]|new[43]|new[44]|new[45]	coref	16-33[135_45]
6-60	843-855	inflammation	abstract[39]|abstract[40]|object[41]|place[42]|animal[43]|abstract[44]|abstract[45]	giv[39]|new[40]|giv[41]|new[42]|new[43]|new[44]|new[45]	_	_
6-61	856-857	.	_	_	_	_

#Text=Chemical depletion of labiar mast cells reduced Ox-driven painful responses and therapeutic topical administration of Δ-9-tetrahydrocannabinol ( THC ) in the vaginal canal alleviated DNFB-induced pain and reduced numbers of accumulated mast cells in the affected tissue .
7-1	858-866	Chemical	abstract[46]	new[46]	_	_
7-2	867-876	depletion	abstract[46]	new[46]	_	_
7-3	877-879	of	abstract[46]	new[46]	_	_
7-4	880-886	labiar	abstract[46]|object[48]	new[46]|giv[48]	coref	7-31[56_48]
7-5	887-891	mast	abstract[46]|object|object[48]	new[46]|giv|giv[48]	_	_
7-6	892-897	cells	abstract[46]|object[48]	new[46]|giv[48]	_	_
7-7	898-905	reduced	_	_	_	_
7-8	906-915	Ox-driven	abstract[49]	new[49]	coref	10-23[84_49]
7-9	916-923	painful	abstract[49]	new[49]	_	_
7-10	924-933	responses	abstract[49]	new[49]	_	_
7-11	934-937	and	_	_	_	_
7-12	938-949	therapeutic	organization[50]	new[50]	_	_
7-13	950-957	topical	organization[50]	new[50]	_	_
7-14	958-972	administration	organization[50]	new[50]	_	_
7-15	973-975	of	organization[50]	new[50]	_	_
7-16	976-1000	Δ-9-tetrahydrocannabinol	organization[50]|abstract	new[50]|new	appos	7-18
7-17	1001-1002	(	_	_	_	_
7-18	1003-1006	THC	abstract	giv	coref	17-13
7-19	1007-1008	)	_	_	_	_
7-20	1009-1011	in	_	_	_	_
7-21	1012-1015	the	place[53]	giv[53]	coref	17-16[145_53]
7-22	1016-1023	vaginal	place[53]	giv[53]	_	_
7-23	1024-1029	canal	place[53]	giv[53]	_	_
7-24	1030-1040	alleviated	_	_	_	_
7-25	1041-1053	DNFB-induced	abstract[54]	giv[54]	coref	8-24[66_54]
7-26	1054-1058	pain	abstract[54]	giv[54]	_	_
7-27	1059-1062	and	_	_	_	_
7-28	1063-1070	reduced	_	_	_	_
7-29	1071-1078	numbers	quantity[55]	new[55]	_	_
7-30	1079-1081	of	quantity[55]	new[55]	_	_
7-31	1082-1093	accumulated	quantity[55]|object[56]	new[55]|giv[56]	coref	16-39[137_56]
7-32	1094-1098	mast	quantity[55]|object[56]	new[55]|giv[56]	_	_
7-33	1099-1104	cells	quantity[55]|object[56]	new[55]|giv[56]	_	_
7-34	1105-1107	in	quantity[55]|object[56]	new[55]|giv[56]	_	_
7-35	1108-1111	the	quantity[55]|object[56]|object[57]	new[55]|giv[56]|new[57]	coref	10-28[0_57]
7-36	1112-1120	affected	quantity[55]|object[56]|object[57]	new[55]|giv[56]|new[57]	_	_
7-37	1121-1127	tissue	quantity[55]|object[56]|object[57]	new[55]|giv[56]|new[57]	_	_
7-38	1128-1129	.	_	_	_	_

#Text=Here , we examined the potential of a common household chemical , 2-methyl-4-isothiazolin-3-one/methylisothiazolinone ( MI ) , to induce contact hypersensitivity reactions and consequent allergy-driven genital pain in ND4 female outbred mice .
8-1	1130-1134	Here	_	_	_	_
8-2	1135-1136	,	_	_	_	_
8-3	1137-1139	we	person	giv	ana	13-1
8-4	1140-1148	examined	_	_	_	_
8-5	1149-1152	the	abstract[59]	new[59]	_	_
8-6	1153-1162	potential	abstract[59]	new[59]	_	_
8-7	1163-1165	of	abstract[59]	new[59]	_	_
8-8	1166-1167	a	abstract[59]|substance[61]	new[59]|new[61]	coref	14-9[119_61]
8-9	1168-1174	common	abstract[59]|substance[61]	new[59]|new[61]	_	_
8-10	1175-1184	household	abstract[59]|place|substance[61]	new[59]|new|new[61]	coref	9-15
8-11	1185-1193	chemical	abstract[59]|substance[61]	new[59]|new[61]	_	_
8-12	1194-1195	,	abstract[59]	new[59]	_	_
8-13	1196-1247	2-methyl-4-isothiazolin-3-one/methylisothiazolinone	abstract[59]|object	new[59]|new	appos	8-15
8-14	1248-1249	(	_	_	_	_
8-15	1250-1252	MI	object	giv	coref	9-1
8-16	1253-1254	)	_	_	_	_
8-17	1255-1256	,	_	_	_	_
8-18	1257-1259	to	_	_	_	_
8-19	1260-1266	induce	_	_	_	_
8-20	1267-1274	contact	_	_	_	_
8-21	1275-1291	hypersensitivity	abstract|event[65]	giv|new[65]	_	_
8-22	1292-1301	reactions	event[65]	new[65]	_	_
8-23	1302-1305	and	_	_	_	_
8-24	1306-1316	consequent	abstract[66]	giv[66]	coref	11-24[98_66]
8-25	1317-1331	allergy-driven	abstract[66]	giv[66]	_	_
8-26	1332-1339	genital	abstract[66]	giv[66]	_	_
8-27	1340-1344	pain	abstract[66]	giv[66]	_	_
8-28	1345-1347	in	abstract[66]	giv[66]	_	_
8-29	1348-1351	ND4	abstract[66]|animal[68]	giv[66]|giv[68]	coref	16-30[0_68]
8-30	1352-1358	female	abstract[66]|person|animal[68]	giv[66]|new|giv[68]	_	_
8-31	1359-1366	outbred	abstract[66]|animal[68]	giv[66]|giv[68]	_	_
8-32	1367-1371	mice	abstract[66]|animal[68]	giv[66]|giv[68]	_	_
8-33	1372-1373	.	_	_	_	_

#Text=MI is a biocide preservative present in soaps , shampoos , vaginal washes , household cleaners , and paints .
9-1	1374-1376	MI	substance	giv	coref	10-12
9-2	1377-1379	is	_	_	_	_
9-3	1380-1381	a	_	_	_	_
9-4	1382-1389	biocide	event	new	_	_
9-5	1390-1402	preservative	substance	new	_	_
9-6	1403-1410	present	_	_	_	_
9-7	1411-1413	in	_	_	_	_
9-8	1414-1419	soaps	substance	new	_	_
9-9	1420-1421	,	_	_	_	_
9-10	1422-1430	shampoos	object	new	_	_
9-11	1431-1432	,	_	_	_	_
9-12	1433-1440	vaginal	object[74]	new[74]	_	_
9-13	1441-1447	washes	object[74]	new[74]	_	_
9-14	1448-1449	,	_	_	_	_
9-15	1450-1459	household	place|object[76]	giv|new[76]	coref|coref	12-9|12-9
9-16	1460-1468	cleaners	object[76]	new[76]	_	_
9-17	1469-1470	,	_	_	_	_
9-18	1471-1474	and	_	_	_	_
9-19	1475-1481	paints	object	new	_	_
9-20	1482-1483	.	_	_	_	_

#Text=Recent evidence suggests that a significant portion of people exposed to MI developed the capacity for an allergic response , showed exacerbated inflammatory responses , and experienced tissue injury in the skin or lungs after exposure .
10-1	1484-1490	Recent	abstract[78]	new[78]	_	_
10-2	1491-1499	evidence	abstract[78]	new[78]	_	_
10-3	1500-1508	suggests	_	_	_	_
10-4	1509-1513	that	_	_	_	_
10-5	1514-1515	a	quantity[79]	new[79]	_	_
10-6	1516-1527	significant	quantity[79]	new[79]	_	_
10-7	1528-1535	portion	quantity[79]	new[79]	_	_
10-8	1536-1538	of	quantity[79]	new[79]	_	_
10-9	1539-1545	people	quantity[79]|person	new[79]|new	_	_
10-10	1546-1553	exposed	_	_	_	_
10-11	1554-1556	to	_	_	_	_
10-12	1557-1559	MI	abstract	giv	coref	11-4
10-13	1560-1569	developed	abstract|event|abstract	new|new|new	coref|coref|coref|none|none|none|coref|coref|coref|none|none|none|coref|coref|coref|none|none|none	11-20[96_0]|12-19[107_0]|13-18[115_0]|10-13[0_96]|10-13[0_107]|10-13[0_115]|11-20[96_0]|12-19[107_0]|13-18[115_0]|10-13[0_96]|10-13[0_107]|10-13[0_115]|11-20[96_0]|12-19[107_0]|13-18[115_0]|10-13[0_96]|10-13[0_107]|10-13[0_115]
10-14	1570-1573	the	abstract[82]	new[82]	_	_
10-15	1574-1582	capacity	abstract[82]	new[82]	_	_
10-16	1583-1586	for	abstract[82]	new[82]	_	_
10-17	1587-1589	an	abstract[82]|event[83]	new[82]|new[83]	_	_
10-18	1590-1598	allergic	abstract[82]|event[83]	new[82]|new[83]	_	_
10-19	1599-1607	response	abstract[82]|event[83]	new[82]|new[83]	_	_
10-20	1608-1609	,	_	_	_	_
10-21	1610-1616	showed	_	_	_	_
10-22	1617-1628	exacerbated	_	_	_	_
10-23	1629-1641	inflammatory	abstract[84]	giv[84]	coref	11-1[91_84]
10-24	1642-1651	responses	abstract[84]	giv[84]	_	_
10-25	1652-1653	,	_	_	_	_
10-26	1654-1657	and	_	_	_	_
10-27	1658-1669	experienced	_	_	_	_
10-28	1670-1676	tissue	object|event[86]	giv|new[86]	_	_
10-29	1677-1683	injury	event[86]	new[86]	_	_
10-30	1684-1686	in	event[86]	new[86]	_	_
10-31	1687-1690	the	event[86]|object[87]|abstract[88]	new[86]|giv[87]|giv[88]	_	_
10-32	1691-1695	skin	event[86]|object[87]|abstract[88]	new[86]|giv[87]|giv[88]	_	_
10-33	1696-1698	or	event[86]|abstract[88]	new[86]|giv[88]	_	_
10-34	1699-1704	lungs	event[86]|abstract[88]|object[89]	new[86]|giv[88]|new[89]	_	_
10-35	1705-1710	after	event[86]|abstract[88]|object[89]	new[86]|giv[88]|new[89]	_	_
10-36	1711-1719	exposure	event[86]|abstract[88]|object[89]|abstract	new[86]|giv[88]|new[89]|new	coref	15-15[124_0]
10-37	1720-1721	.	_	_	_	_

#Text=Allergic responses to MI have also been linked to vulvar dermatitis , but no connections between such dermatoses and the later development of vulvar pain have been made in the published clinical literature .
11-1	1722-1730	Allergic	abstract[91]	giv[91]	_	_
11-2	1731-1740	responses	abstract[91]	giv[91]	_	_
11-3	1741-1743	to	abstract[91]	giv[91]	_	_
11-4	1744-1746	MI	abstract[91]|abstract	giv[91]|giv	coref	15-4
11-5	1747-1751	have	_	_	_	_
11-6	1752-1756	also	_	_	_	_
11-7	1757-1761	been	_	_	_	_
11-8	1762-1768	linked	_	_	_	_
11-9	1769-1771	to	_	_	_	_
11-10	1772-1778	vulvar	abstract[93]	new[93]	_	_
11-11	1779-1789	dermatitis	abstract[93]	new[93]	_	_
11-12	1790-1791	,	_	_	_	_
11-13	1792-1795	but	_	_	_	_
11-14	1796-1798	no	abstract[94]	new[94]	_	_
11-15	1799-1810	connections	abstract[94]	new[94]	_	_
11-16	1811-1818	between	abstract[94]	new[94]	_	_
11-17	1819-1823	such	abstract[94]|abstract[95]	new[94]|new[95]	_	_
11-18	1824-1834	dermatoses	abstract[94]|abstract[95]	new[94]|new[95]	_	_
11-19	1835-1838	and	_	_	_	_
11-20	1839-1842	the	abstract[96]	new[96]	_	_
11-21	1843-1848	later	abstract[96]	new[96]	_	_
11-22	1849-1860	development	abstract[96]	new[96]	_	_
11-23	1861-1863	of	abstract[96]	new[96]	_	_
11-24	1864-1870	vulvar	abstract[96]|object|abstract[98]	new[96]|giv|giv[98]	coref|coref	13-21[116_98]|13-21[116_98]
11-25	1871-1875	pain	abstract[96]|abstract[98]	new[96]|giv[98]	_	_
11-26	1876-1880	have	_	_	_	_
11-27	1881-1885	been	_	_	_	_
11-28	1886-1890	made	_	_	_	_
11-29	1891-1893	in	_	_	_	_
11-30	1894-1897	the	abstract[99]	new[99]	_	_
11-31	1898-1907	published	abstract[99]	new[99]	_	_
11-32	1908-1916	clinical	abstract[99]	new[99]	_	_
11-33	1917-1927	literature	abstract[99]	new[99]	_	_
11-34	1928-1929	.	_	_	_	_

#Text=Recently , Reed and colleagues identified exposures to household and workplace chemicals as a possible risk factor for the development of vulvodynia .
12-1	1930-1938	Recently	_	_	_	_
12-2	1939-1940	,	_	_	_	_
12-3	1941-1945	Reed	person	new	_	_
12-4	1946-1949	and	_	_	_	_
12-5	1950-1960	colleagues	person	new	_	_
12-6	1961-1971	identified	_	_	_	_
12-7	1972-1981	exposures	abstract[102]	new[102]	coref	13-15[114_102]
12-8	1982-1984	to	abstract[102]	new[102]	_	_
12-9	1985-1994	household	abstract[102]|place	new[102]|giv	_	_
12-10	1995-1998	and	abstract[102]	new[102]	_	_
12-11	1999-2008	workplace	abstract[102]|place|substance[105]	new[102]|new|new[105]	_	_
12-12	2009-2018	chemicals	abstract[102]|substance[105]	new[102]|new[105]	_	_
12-13	2019-2021	as	_	_	_	_
12-14	2022-2023	a	_	_	_	_
12-15	2024-2032	possible	_	_	_	_
12-16	2033-2037	risk	abstract	new	_	_
12-17	2038-2044	factor	_	_	_	_
12-18	2045-2048	for	_	_	_	_
12-19	2049-2052	the	event[107]	new[107]	_	_
12-20	2053-2064	development	event[107]	new[107]	_	_
12-21	2065-2067	of	event[107]	new[107]	_	_
12-22	2068-2078	vulvodynia	event[107]|abstract	new[107]|giv	coref	14-7
12-23	2079-2080	.	_	_	_	_

#Text=Our previously published mouse models demonstrated the biological plausibility of the epidemiological link between chemical exposures and the development of genital pain .
13-1	2081-2084	Our	person|abstract[111]	giv|giv[111]	ana|ana	15-1|15-1
13-2	2085-2095	previously	abstract[111]	giv[111]	_	_
13-3	2096-2105	published	abstract[111]	giv[111]	_	_
13-4	2106-2111	mouse	animal|abstract[111]	giv|giv[111]	_	_
13-5	2112-2118	models	abstract[111]	giv[111]	_	_
13-6	2119-2131	demonstrated	_	_	_	_
13-7	2132-2135	the	abstract[112]	new[112]	_	_
13-8	2136-2146	biological	abstract[112]	new[112]	_	_
13-9	2147-2159	plausibility	abstract[112]	new[112]	_	_
13-10	2160-2162	of	abstract[112]	new[112]	_	_
13-11	2163-2166	the	abstract[112]|abstract[113]	new[112]|new[113]	coref	14-3[117_113]
13-12	2167-2182	epidemiological	abstract[112]|abstract[113]	new[112]|new[113]	_	_
13-13	2183-2187	link	abstract[112]|abstract[113]	new[112]|new[113]	_	_
13-14	2188-2195	between	abstract[112]|abstract[113]	new[112]|new[113]	_	_
13-15	2196-2204	chemical	abstract[112]|abstract[113]|abstract[114]	new[112]|new[113]|giv[114]	_	_
13-16	2205-2214	exposures	abstract[112]|abstract[113]|abstract[114]	new[112]|new[113]|giv[114]	_	_
13-17	2215-2218	and	abstract[112]|abstract[113]|abstract[114]	new[112]|new[113]|giv[114]	_	_
13-18	2219-2222	the	abstract[112]|abstract[113]|abstract[114]|abstract[115]	new[112]|new[113]|giv[114]|new[115]	_	_
13-19	2223-2234	development	abstract[112]|abstract[113]|abstract[114]|abstract[115]	new[112]|new[113]|giv[114]|new[115]	_	_
13-20	2235-2237	of	abstract[112]|abstract[113]|abstract[114]|abstract[115]	new[112]|new[113]|giv[114]|new[115]	_	_
13-21	2238-2245	genital	abstract[112]|abstract[113]|abstract[114]|abstract[115]|abstract[116]	new[112]|new[113]|giv[114]|new[115]|giv[116]	coref	15-21[126_116]
13-22	2246-2250	pain	abstract[112]|abstract[113]|abstract[114]|abstract[115]|abstract[116]	new[112]|new[113]|giv[114]|new[115]|giv[116]	_	_
13-23	2251-2252	.	_	_	_	_

#Text=However , a specific link between vulvodynia and a known environmental chemical does not yet exist .
14-1	2253-2260	However	_	_	_	_
14-2	2261-2262	,	_	_	_	_
14-3	2263-2264	a	abstract[117]	giv[117]	_	_
14-4	2265-2273	specific	abstract[117]	giv[117]	_	_
14-5	2274-2278	link	abstract[117]	giv[117]	_	_
14-6	2279-2286	between	abstract[117]	giv[117]	_	_
14-7	2287-2297	vulvodynia	abstract[117]|substance	giv[117]|giv	_	_
14-8	2298-2301	and	abstract[117]	giv[117]	_	_
14-9	2302-2303	a	abstract[117]|substance[119]	giv[117]|giv[119]	_	_
14-10	2304-2309	known	abstract[117]|substance[119]	giv[117]|giv[119]	_	_
14-11	2310-2323	environmental	abstract[117]|substance[119]	giv[117]|giv[119]	_	_
14-12	2324-2332	chemical	abstract[117]|substance[119]	giv[117]|giv[119]	_	_
14-13	2333-2337	does	_	_	_	_
14-14	2338-2341	not	_	_	_	_
14-15	2342-2345	yet	_	_	_	_
14-16	2346-2351	exist	_	_	_	_
14-17	2352-2353	.	_	_	_	_

#Text=We suggest that MI is a plausible candidate for an environmental irritant/allergen , and that exposure to MI might drive allergy-provoked pain .
15-1	2354-2356	We	person	giv	ana	16-3
15-2	2357-2364	suggest	_	_	_	_
15-3	2365-2369	that	_	_	_	_
15-4	2370-2372	MI	person	giv	coref	15-6[122_0]
15-5	2373-2375	is	_	_	_	_
15-6	2376-2377	a	person[122]	giv[122]	coref	15-18[0_122]
15-7	2378-2387	plausible	person[122]	giv[122]	_	_
15-8	2388-2397	candidate	person[122]	giv[122]	_	_
15-9	2398-2401	for	person[122]	giv[122]	_	_
15-10	2402-2404	an	person[122]|abstract[123]	giv[122]|new[123]	_	_
15-11	2405-2418	environmental	person[122]|abstract[123]	giv[122]|new[123]	_	_
15-12	2419-2436	irritant/allergen	person[122]|abstract[123]	giv[122]|new[123]	_	_
15-13	2437-2438	,	_	_	_	_
15-14	2439-2442	and	_	_	_	_
15-15	2443-2447	that	abstract[124]	giv[124]	_	_
15-16	2448-2456	exposure	abstract[124]	giv[124]	_	_
15-17	2457-2459	to	abstract[124]	giv[124]	_	_
15-18	2460-2462	MI	abstract[124]|abstract	giv[124]|giv	coref	16-6
15-19	2463-2468	might	_	_	_	_
15-20	2469-2474	drive	_	_	_	_
15-21	2475-2491	allergy-provoked	abstract[126]	giv[126]	_	_
15-22	2492-2496	pain	abstract[126]	giv[126]	_	_
15-23	2497-2498	.	_	_	_	_

#Text=Here , we repeatedly applied MI dissolved in saline ( a surrogate for water-based cleansers that typically contain MI as a preservative ) topically within the vaginal canals of mice and characterized consequent allergic inflammation , accumulation of mast cells , and ano-genital sensitivity to pressure .
16-1	2499-2503	Here	_	_	_	_
16-2	2504-2505	,	_	_	_	_
16-3	2506-2508	we	person	giv	ana	17-1
16-4	2509-2519	repeatedly	_	_	_	_
16-5	2520-2527	applied	_	_	_	_
16-6	2528-2530	MI	substance	giv	coref	16-19
16-7	2531-2540	dissolved	_	_	_	_
16-8	2541-2543	in	_	_	_	_
16-9	2544-2550	saline	substance	new	_	_
16-10	2551-2552	(	_	_	_	_
16-11	2553-2554	a	object[130]	new[130]	_	_
16-12	2555-2564	surrogate	object[130]	new[130]	_	_
16-13	2565-2568	for	object[130]	new[130]	_	_
16-14	2569-2580	water-based	object[130]|substance[131]	new[130]|new[131]	_	_
16-15	2581-2590	cleansers	object[130]|substance[131]	new[130]|new[131]	_	_
16-16	2591-2595	that	_	_	_	_
16-17	2596-2605	typically	_	_	_	_
16-18	2606-2613	contain	_	_	_	_
16-19	2614-2616	MI	substance	giv	_	_
16-20	2617-2619	as	_	_	_	_
16-21	2620-2621	a	_	_	_	_
16-22	2622-2634	preservative	_	_	_	_
16-23	2635-2636	)	_	_	_	_
16-24	2637-2646	topically	_	_	_	_
16-25	2647-2653	within	_	_	_	_
16-26	2654-2657	the	place[133]	new[133]	_	_
16-27	2658-2665	vaginal	place[133]	new[133]	_	_
16-28	2666-2672	canals	place[133]	new[133]	_	_
16-29	2673-2675	of	place[133]	new[133]	_	_
16-30	2676-2680	mice	place[133]|animal	new[133]|giv	_	_
16-31	2681-2684	and	_	_	_	_
16-32	2685-2698	characterized	_	_	_	_
16-33	2699-2709	consequent	abstract[135]	giv[135]	_	_
16-34	2710-2718	allergic	abstract[135]	giv[135]	_	_
16-35	2719-2731	inflammation	abstract[135]	giv[135]	_	_
16-36	2732-2733	,	_	_	_	_
16-37	2734-2746	accumulation	object[136]	new[136]	_	_
16-38	2747-2749	of	object[136]	new[136]	_	_
16-39	2750-2754	mast	object[136]|object[137]	new[136]|giv[137]	_	_
16-40	2755-2760	cells	object[136]|object[137]	new[136]|giv[137]	_	_
16-41	2761-2762	,	_	_	_	_
16-42	2763-2766	and	_	_	_	_
16-43	2767-2778	ano-genital	abstract[138]	giv[138]	coref	17-24[148_138]
16-44	2779-2790	sensitivity	abstract[138]	giv[138]	_	_
16-45	2791-2793	to	abstract[138]	giv[138]	_	_
16-46	2794-2802	pressure	abstract[138]|abstract	giv[138]|new	_	_
16-47	2803-2804	.	_	_	_	_

#Text=We also assessed the effects of therapeutic and preventive administration of topical THC treatments in the vaginal canal on mast cell abundance and painful sensitivity .
17-1	2805-2807	We	person	giv	_	_
17-2	2808-2812	also	_	_	_	_
17-3	2813-2821	assessed	_	_	_	_
17-4	2822-2825	the	abstract[141]	new[141]	_	_
17-5	2826-2833	effects	abstract[141]	new[141]	_	_
17-6	2834-2836	of	abstract[141]	new[141]	_	_
17-7	2837-2848	therapeutic	abstract[141]|organization[142]	new[141]|new[142]	_	_
17-8	2849-2852	and	abstract[141]|organization[142]	new[141]|new[142]	_	_
17-9	2853-2863	preventive	abstract[141]|organization[142]	new[141]|new[142]	_	_
17-10	2864-2878	administration	abstract[141]|organization[142]	new[141]|new[142]	_	_
17-11	2879-2881	of	abstract[141]|organization[142]	new[141]|new[142]	_	_
17-12	2882-2889	topical	abstract[141]|organization[142]|abstract[144]	new[141]|new[142]|new[144]	_	_
17-13	2890-2893	THC	abstract[141]|organization[142]|abstract|abstract[144]	new[141]|new[142]|giv|new[144]	_	_
17-14	2894-2904	treatments	abstract[141]|organization[142]|abstract[144]	new[141]|new[142]|new[144]	_	_
17-15	2905-2907	in	abstract[141]|organization[142]|abstract[144]	new[141]|new[142]|new[144]	_	_
17-16	2908-2911	the	abstract[141]|organization[142]|abstract[144]|place[145]	new[141]|new[142]|new[144]|giv[145]	_	_
17-17	2912-2919	vaginal	abstract[141]|organization[142]|abstract[144]|place[145]	new[141]|new[142]|new[144]|giv[145]	_	_
17-18	2920-2925	canal	abstract[141]|organization[142]|abstract[144]|place[145]	new[141]|new[142]|new[144]|giv[145]	_	_
17-19	2926-2928	on	abstract[141]|organization[142]|abstract[144]|place[145]	new[141]|new[142]|new[144]|giv[145]	_	_
17-20	2929-2933	mast	abstract[141]|organization[142]|abstract[144]|place[145]|abstract[147]	new[141]|new[142]|new[144]|giv[145]|new[147]	_	_
17-21	2934-2938	cell	abstract[141]|organization[142]|abstract[144]|place[145]|place|abstract[147]	new[141]|new[142]|new[144]|giv[145]|new|new[147]	_	_
17-22	2939-2948	abundance	abstract[141]|organization[142]|abstract[144]|place[145]|abstract[147]	new[141]|new[142]|new[144]|giv[145]|new[147]	_	_
17-23	2949-2952	and	abstract[141]|organization[142]|abstract[144]|place[145]	new[141]|new[142]|new[144]|giv[145]	_	_
17-24	2953-2960	painful	abstract[141]|organization[142]|abstract[144]|place[145]|abstract[148]	new[141]|new[142]|new[144]|giv[145]|giv[148]	_	_
17-25	2961-2972	sensitivity	abstract[141]|organization[142]|abstract[144]|place[145]|abstract[148]	new[141]|new[142]|new[144]|giv[145]|giv[148]	_	_
17-26	2973-2974	.	_	_	_	_
